N@N

SUCAMPO PHARMACEUTICALS-CL A (NASDAQ:SCMP), Down By 6.07% ($0.47) From $7.740 After BUYINS.NET Report Predicted Weakness After

^{Published on 2012-05-30 13:42:01 - WOPRAI}
 

May 30, 2012 / M2 PRESSWIRE / BUYINS.NET, www.buyins.net , a provider of unique trading technologies, released a report on Tuesday, May 8th 2012 stating that SUCAMPO PHARMACEUTICALS-CL A (NASDAQ:SCMP) was expected to be Down After its earnings release. Click here to view the BUYINS.NET report: http://www.buyins.net/releases/?sym=scmp&id=272305

At the time this story was written, SUCAMPO PHARMACEUTICALS-CL A (NASDAQ:SCMP) is Down By 6.07% ($0.47) From $7.740 since the BUYINS.NET report was released.

The movement of stock prices in the days and weeks leading to and following earnings announcements may follow a predictable pattern. Most companies stock price histories show random or unpredictable movements around earnings dates. But some seem to repeat the same pattern quarter after quarter, year after year. The specific technology used to make these predictions is available for a low monthly fee at http://www.squeezetrigger.com/services/strat/mh.php

SUCAMPO PHARMACEUTICALS-CL A (NASDAQ:SCMP) - Sucampo Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs based on prostones primarily in the Americas, Europe, and Asia. It offers prostone-based compounds for the treatment of gastrointestinal, vascular, respiratory, and central nervous system diseases and disorders. The company primarily markets Amitiza for the treatment of chronic idiopathic constipation in adults, as well as for irritable bowel syndrome with constipation in adult women. It also offers Rescula (unoprostone isopropyl) for the treatment of open-angle glaucoma and ocular hypertension. In addition, the company is developing Amitiza for the treatment of opioid-induced bowel dysfunction, which completed two Phase III clinical trials; Cobiprostone for the prevention of non-steroidal anti-inflammatory drug induced ulcers, which completed a Phase IIa clinical trial; SPI-017, a Phase I clinical trial product, for the treatment of Peripheral arterial disease; and SPI-3608 for the treatment of spinal stenosis, which is under preclinical trial. Additionally, it is conducting a preclinical trial of Rescula for dry age related macular degeneration; and preclinical trials of Cobiprostone for the treatment of chronic obstructive pulmonary disease and wound healing. Sucampo Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Bethesda, Maryland.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market-maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market-maker surveillance system tracking market makers in all stocks to determine Price Friction and compliance with new "Fair Market-Making Requirements".

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and all Threshold Security Lists daily for which stocks have naked short positions.

INVESTMENTS & TRADING

SqueezeTrigger -- 28 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts next move in stocks.

GATS -- tracks and quantifies known trading strategies.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. SUCAMPO PHARMACEUTICALS-CL A (NASDAQ:SCMP) has not approved the statements made in this release. Please read our report and visit our web site, http://www.buyins.net, for complete risks and disclosures.

Contact: BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net http://www.buyins.net